Orexigen Insists Revised Contrave Data Should Not Affect Review Timeline
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Although Orexigen Therapeutics needed to correct data included in the NDA for its Contrave obesity drug, the company appears to have weathered some shareholder concern and may be on an unchanged timeline for FDA consideration and approval of its application